Evotec AG (EVT.DE)

9,64 -4,54 (-32,02%) Börsenschluss: 05:41PM CEST

Evotec AG

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 5.086

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Mario Polywka DPHIL, Ph.D.	Interim CEO, Member of the Management Board & Member of the Supervisory Board	N/A	N/A	1963
Dr. Werner Lanthaler M.B.A., MPA, Ph.D.	Member of Management Board	1,32M	N/A	1968
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	804k	N/A	1964
Dr. Craig Johnstone Ph.D.	COO & Member of Management Board	712k	N/A	1970
Dr. Matthias Evers Ph.D.	Chief Business Officer & Member of Management Board	636k	N/A	1973
Ms. Laetitia Rouxel	CFO & Member of Management Board	N/A	N/A	1974
Ms. Anja Bosler	Principal Accounting Officer and Senior Vice President of Group Accounting	N/A	N/A	N/A
Mr. Volker Braun	Executive VP and Head of Global Investor Relations & ESG	N/A	N/A	N/A
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/A	N/A	N/A
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Corporate Governance

Evotec AGs ISS Governance QualityScore, Stand 1. April 2024, lautet 6. Die grundlegenden Scores sind Audit: 4, Vorstand: 4, Shareholderrechte: 1, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.